Baird Medical Showcases Advanced Microwave Ablation Technology at the 2025 ACS Clinical Congress

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) is exhibiting at the American College of Surgeons Clinical Congress 2025 in Chicago from October 5–7, 2025. The company is at Booth 1061 presenting live, hands-on demonstrations of its minimally invasive Microwave Ablation (MWA) devices. Demonstrations highlight precision and efficiency for treating thyroid nodules, breast disease, and liver cancer, and aim to engage surgeons and clinical leaders on expanding MWA applications in interventional medicine. Participation underscores Baird Medical's focus on clinical collaboration and advancing patient care through its MWA technology.

NEW YORK, Oct. 6, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, is participating in the American College of Surgeons (ACS) Clinical Congress 2025 in Chicago, IL. The prestigious event is being held from October 5-7 and brings together tens of thousands of surgeons from around the world to explore the latest advancements in surgical care.

The ACS, established in 1913, is the world's largest and most influential organization for surgeons, boasting more than 90,000 members across 144 countries. The annual Clinical Congress serves as a key platform for discussing surgical advancements, exploring new technologies, and fostering collaboration within the medical community.

Throughout the congress, Baird Medical is featuring its cutting-edge MWA devices at Booth 1061. The Company is conducting live, hands-on demonstrations showcasing the technology's precision and efficiency in treating a range of conditions, including thyroid nodules, breast disease, and liver cancer. This interactive exhibit provides surgeons and medical professionals the opportunity to experience firsthand the benefits of this minimally invasive treatment modality.

Baird Medical's participation underscores its commitment to collaborating with the surgical community to advance patient care. The Company aims to engage with clinical leaders to discuss the expanding applications of MWA and its role in the future of interventional medicine.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-advanced-microwave-ablation-technology-at-the-2025-acs-clinical-congress-302575470.html

SOURCE BDMD

FAQ

When and where is Baird Medical (BDMD) presenting MWA technology at ACS Clinical Congress 2025?

Baird Medical is exhibiting at the ACS Clinical Congress in Chicago from October 5–7, 2025 at Booth 1061.

What MWA procedures is BDMD demonstrating at the October 2025 ACS meeting?

BDMD is demonstrating MWA applications for thyroid nodules, breast disease, and liver cancer with live hands-on sessions.

How can surgeons attend BDMD's live demonstrations at ACS Clinical Congress 2025?

Surgeons can visit Booth 1061 during the October 5–7 congress to participate in live, hands-on demonstrations.

What are the expected benefits of BDMD's microwave ablation technology shown at ACS 2025?

The demonstrations emphasize minimally invasive treatment, device precision, and procedural efficiency for selected tumors and nodules.

Will BDMD discuss clinical applications and future uses of MWA at the ACS 2025 conference?

Yes. BDMD aims to engage clinical leaders to discuss expanding MWA applications and its role in interventional medicine.

Is Baird Medical (BDMD) a participant in major surgical conferences beyond ACS Clinical Congress 2025?

BDMD is participating in ACS Clinical Congress 2025; engagement at other conferences was not disclosed in this announcement.